As a nurse practitioner my plan of care would include

As a nurse practitioner my plan of care would include extensive education on prophylaxis
with emphasis on hand washing as well as addressing patient specific symptoms after reviewing
past medical history and medication list. Frequent hand washing can reduce the spread of
respiratory viruses in all ages and can reduce transmission from children to other household
members (Arcangelo and Peterson, 2013).
References
Arcangelo, V. P., & Peterson, A. M. (Eds.). (2013). Pharmacotherapeutics for advanced
practice: A practical approach (3rd ed.). Ambler, PA: Lippincott Williams & Wilkins.
Drugs.com. (2016). Atrovent HFA. Retrieved from
Fashner, J., Ericson, K., & Werner, S. (2012). Treatment of the common cold in children and
adults. American Family Physician , 86 (2), 153-159.
Jacobs, S. E., Lamson, D. M., St. George, K., et al. (2013). Human rhinoviruses. Clinical
Microbiology Reviews, 26(1), 135–162.
KinyonMunch, K. (2011). What do you tell parents when their child is sick with the common
cold?. Journal For Specialists In Pediatric Nursing , 16 (1), 8-15. doi:10.1111/j.1744-
6155.2010.00262.x. Retrieved from Walden Library databases
Mayo Clinic. (2016). Common Cold. Retrieved from -
conditions/common-cold/symptoms-causes/dxc-20199808

NURS 6521N-36 Advanced Pharmacology
Discussion Post Week 4 – Pharmacotherapy of Respiratory Disorders
Cynthia Nwokocha
June 19, 2017
Pharmacotherapy for Respiratory Disorders
Chronic Bronchitis (CB) is a component of COPD and is the fourth leading cause of
death in the United States (Arcangelo & Andrew, 2013). The typical signs of chronic bronchitis
are increased dyspnea, increased purulence, productive cough and increased sputum production
for 3 months per year for at least 2 years. CB can be contracted by everyone; however, it is seen
commonly in those 45 years and older population but also very common in the elderly, and even
more so, it is common in men than women (Lung Institute, 2016).
Drugs, Treatment, and Risk Factors
The goals of drug treatment for CB is to reduce the severity of the chronic symptoms and
ameliorate acute exacerbations with prolonged infection free intervals (Arcangelo & Andrew,
2013). Treatment regimen would include bronchodilators, antibiotics, steroids, vaccinations and
oxygen therapy. In some instances, surgery or stem cell therapy may be indicated. In addition,
pulmonary rehabilitation will be added as it the one of the important components in the treatment
of CB. However, the first line of treatment for chronic bronchitis is antimicrobial therapy. This
would consist of ampicillin, cephalosporin and fluoroquinolones.

However, these medications need to administer carefully and the patient needs to be
checked and monitored for any hypersensitivity. This can be challenging in an older patient.
Older patients can have other existing conditions that can counter act the effects of the drug. For
example, fluoroquinolones should be used cautiously in patients with known prolongation of the
QT interval, patients with uncorrected hypokalemia, or any one receiving antiarrhythmic agents.